When does the Takhzyro (lanadelumab) patent expire?
I can’t answer yet because the question looks incomplete (“Takhzyro patent wer…”). The exact expiry date depends on which patent family and jurisdiction you mean (for example, U.S. vs. Europe), and patent listings often include multiple patents with different end dates.
If you tell me the country (e.g., U.S., EP/UK, Germany) or share the exact wording you meant (for example, “when does the patent expire” or “what patents cover it”), I can narrow it down to the relevant patents.
What patents cover Takhzyro, and when does exclusivity end?
Coverage can include multiple layers:
- Core composition of matter or formulation patents
- Method-of-use patents
- Pediatric/exclusivity extensions (where applicable)
- Additional “secondary” patents that can extend protection even after the earliest filing
A practical way to identify the controlling patents and the likely end dates is to check a dedicated patent tracker like DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Takhzyro” or “lanadelumab”).
Are there generic or biosimilar versions available before patent expiry?
Takhzyro is a biologic, so “generic” is usually not the right term; biosimilars are the relevant category. Whether a biosimilar can launch depends on the specific patent landscape and whether any patents are still in force, plus the regulatory pathway and any litigation stays.
If you share the region you care about (U.S./EU/UK), I can explain the typical pathway and what usually blocks early entry.
Quick clarification so I can give an exact answer
Reply with one of these:
1) “Takhzyro patent expiry in the U.S.”
2) “Takhzyro patent expiry in Europe (EP/UK/Germany)”
3) The rest of your question after “Takhzyro patent wer…”
Sources:
1. https://www.drugpatentwatch.com/